Pfizer (PFE) is ending a late-stage trial of its once-daily GLP-1 pill, Danuglipron, after a participant experienced a liver ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White ...

Market OverviewThe Global Osteoarthritis Pain Drugs Market is valued at USD 10.32 Billion in 2023 and is projected to reach a value of USD 17.96 Billion by 2032 at a CAGR (Compound Annual Growth Rate) ...

The LATAM pain management drugs market was valued at $2,683.82 million in 2019, and is projected to reach $3,383.20 million by 2027, registering a CAGR of 3.5% from 2020 to 2027. The length of pain ...

The Heart Failure Drugs Market is poised for a transformative decade between 2025 and 2035. As heart failure continues to ...

Pfizer PFE underwent analysis by 4 analysts in the last quarter ... While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for ...

Asthma Drugs Market Oral and injectable forms are expanding, especially for patients with severe asthma and those undergoing biologic treat ...

An exploratory analysis shows a reduction in extrathoracic metastases and prolonged time to progression or death due to any ...

Five years ago, volunteers rolled up their sleeves in the first clinical trial of a vaccine against COVID-19, as the new ...

With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals ...